year 17, Issue 2 (March - April 2023)                   Iran J Med Microbiol 2023, 17(2): 267-269 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Elahi Y, Mazaheri Nezhad Fard R. Is the Antibiotic Era Joint the History?. Iran J Med Microbiol 2023; 17 (2) :267-269
1- Department of Genetics, Faculty of Life Sciences, Islamic Azad University Tehran North Branch, Tehran, Iran
2- Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran ,
Abstract:   (831 Views)

For the last few years, antibiotic resistance has become one of the major concerns within medical society. On one hand, pathogens have mostly acquired resistance against the major conventional antibiotics used in the treatment of microbial infections. These included even first-line antibiotics, which are critical in the treatment of severe infections. This catastrophic situation has occurred due to the extensively irresponsible use of antibiotics in humans and veterinary medicines, agriculture, aquaculture and animal breeding. On the other hand, the long absence of novel antibiotic introduction to the market by the pharmaceutical industry has exacerbated the situation. In fact, industrial giants are not interested in, or at least have lost their fascination with, the development of novel formulations. One of the greatest reasons that pharmaceutical industries are not fascinated by antimicrobial development is that the process is a greatly expensive wander since the development of novel antimicrobial drugs costs an estimated $1.5 billion [1] while incomes from the marketing of the antimicrobial agent include nearly $46 million annually. As far as it is known, very few novel antibiotics have been commercialized by the pharmaceutical industries within the last three decades, mostly semi or fully synthetic ones, while the necessity of these biochemicals is urgently felt. As a response to this failure, medical researchers have shifted to other antimicrobial alternatives, including bacteriophages, short peptides, bacteriocins and herbals. However, the potential rapid effectiveness of conventional antibiotics may force researchers to rethink further investigations of microbial antibiotics. But (as always there must be a big “BUT”) why?

Full-Text [PDF 336 kb]   (224 Downloads) |   |   Full-Text (HTML)  (94 Views)  
Type of Study: Letter to the Editor | Subject: Antibiotic Resistance
Received: 2022/08/28 | Accepted: 2022/12/25 | ePublished: 2023/03/30

1. Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy. 2017;121(10):1025-30. [DOI:10.1016/j.healthpol.2017.07.011] [PMID]
2. Khelaifia S, Drancourt M. Susceptibility of archaea to antimicrobial agents: applications to clinical microbiology. Clin Microbiol Infect. 2012;18(9):841-8. [DOI:10.1111/j.1469-0691.2012.03913.x] [PMID]
3. Levy MG. Smithsonian Magazine. 2020.
4. Muller C. Antibiotics and antimicrobials resistance: mechanisms and new strategies to fight resistant bacteria. 2022. p. 400. [DOI:10.3390/antibiotics11030400] [PMID] [PMCID]
5. Oesterreicher Z, Eberl S, Wulkersdorfer B, Matzneller P, Eder C, van Duijn E, et al. Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clin Pharmacokinet. 2022;61(5):697-707. [DOI:10.1007/s40262-021-01091-1] [PMID] [PMCID]
6. Modi S, Inwati GK, Gacem A, Saquib Abullais S, Prajapati R, Yadav VK, et al. Nanostructured Antibiotics and Their Emerging Medicinal Applications: An Overview of Nanoantibiotics. Antibiotics [Internet]. 2022; 11(6). [DOI:10.3390/antibiotics11060708] [PMID] [PMCID]
7. Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, et al. Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics [Internet]. 2022; 11(2). [DOI:10.3390/antibiotics11020200] [PMID] [PMCID]
8. University of Liverpool Website. Liverpool scientists develop synthetic antibiotics that could save millions of lives 2022. Available from: []

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc